Canakinumab vs placebo or usual care
Clinical improvement D60 or above
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only
No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Canakinumab vs placebo or usual care
WHO progression score (level 7 or above) D28
Canakinumab showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.72 [0.44, 1.2]2 studies · 499 participantsLow
Canakinumab vs placebo or usual care
WHO Clinical Progression Score of level 7 or above D60 or above
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Canakinumab vs placebo or usual care
All‐cause mortality D28
Canakinumab showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.75 [0.39, 1.42]2 studies · 499 participantsLow
Canakinumab vs placebo or usual care
All‐cause mortality D60 or more
It is very uncertain whether canakinumab changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
1 finding from 1 review
- RR 0.55 [0.16, 1.91]1 study · 45 participantsVery low
Canakinumab vs placebo or usual care
Adverse events
Canakinumab showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).
1 finding from 1 review
- RR 1.02 [0.86, 1.21]1 study · 454 participantsModerate
Canakinumab vs placebo or usual care
Serious adverse eventsÂ
Canakinumab showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.8 [0.57, 1.13]2 studies · 499 participantsLow
Anakinra vs placebo or usual care
Clinical improvement D60 or above
It is very uncertain whether anakinra changes clinical improvement D60 or above compared with standard care/placebo (very low certainty).
1 finding from 1 review
- RR 0.93 [0.78, 1.12]1 study · 115 participantsVery low
Canakinumab vs placebo or usual care
Time to clinical improvement
Canakinumab showed no clear difference in time to clinical improvement compared with standard care/placebo (moderate certainty).
1 finding from 1 review
- HR 1.06 [0.87, 1.29]1 study · 454 participantsModerate
Canakinumab vs placebo or usual care
Time to WHO Clinical Progression Score of level 7 or above
Canakinumab showed no clear difference in time to WHO Clinical Progression Score of level 7 or above compared with standard care/placebo (low certainty).
1 finding from 1 review
- HR 0.8 [0.47, 1.36]1 study · 454 participantsLow
Canakinumab vs placebo or usual care
Time to death
Canakinumab showed no clear difference in time to death compared with standard care/placebo (low certainty).
1 finding from 1 review
- HR 0.71 [0.36, 1.43]2 studies · 499 participantsLow
Anakinra vs placebo or usual care
WHO progression score (level 7 or above) D28
Anakinra showed no clear difference in WHO Clinical Progression Score of level 7 or above D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.67 [0.36, 1.22]2 studies · 722 participantsLow
Anakinra vs placebo or usual care
WHO Clinical Progression Score of level 7 or above D60 or above
Anakinra may leads to lower WHO Clinical Progression Score of level 7 or above D60 or above compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.54 [0.3, 0.96]1 study · 606 participantsLow
Anakinra vs placebo or usual care
All‐cause mortality D28
Anakinra showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.69 [0.34, 1.39]2 studies · 722 participantsLow
Anakinra vs placebo or usual care
All‐cause mortality D60 or more
It is very uncertain whether anakinra changes all‐cause mortality D60 or above compared with standard care/placebo (very low certainty).
1 finding from 1 review
- RR 1.03 [0.68, 1.56]4 studies · 1633 participantsVery low
Anakinra vs placebo or usual care
Adverse events
Anakinra showed no clear difference in adverse events compared with standard care/placebo (moderate certainty).
1 finding from 1 review
- RR 1.02 [0.94, 1.11]2 studies · 722 participantsModerate
Anakinra vs placebo or usual care
Serious adverse eventsÂ
Anakinra showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
1 finding from 1 review
- RR 0.95 [0.58, 1.56]2 studies · 722 participantsLow
Anakinra vs placebo or usual care
Time to clinical improvement
Anakinra showed no clear difference in time to clinical improvement compared with standard care/placebo (low certainty).
1 finding from 1 review
- HR 1.07 [0.91, 1.26]4 studies · 1633 participantsLow
Fluvoxamine plus standard care vs placebo + standard care
All‐cause mortality (at day 28) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause mortality (at day 28) compared with placebo plus standard care (low certainty).
1 finding from 1 review
- RR 0.69 [0.38, 1.27]2 studies · 1649 participantsLow
Fluvoxamine plus standard care vs placebo + standard care
All‐cause admission to hospital or death (before hospital admission) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause admission to hospital or death (before hospital admission) compared with placebo plus standard care (low certainty).
1 finding from 1 review
- RR 0.55 [0.16, 1.89]2 studies · 1649 participantsLow